Insulin glargine for type 2 diabetes.
Insulin glargine is a biosynthetic human insulin analogue that controls blood glucose levels over 24 hours without a pronounced peak. In most studies in patients with type 2 diabetes mellitus (DM), insulin glargine did not significantly reduce fasting blood glucose, fasting plasma glucose or hemoglobin A1c compared to NPH insulin. Most trials showed a statistically significant decrease in the incidence of nocturnal and symptomatic hypoglycemia. This may not be as much of a concern in most patients with type 2 DM compared to type 1 DM. Current evidence suggests that patients who are adequately controlled with NPH insulin will not gain additional benefit from insulin glargine.
Farah
F
Hemraj
Kirsten
K
Garces
D002170:Canada; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D007328:Insulin